Seres Therapeutics

MCRB · Nasdaq · United States

Share price · MCRB

$1.44-2.90 (-66.82%) 3M

close as of 2026-11-18 · 24h delayed · vol 43K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MCRB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-14.1%

    Nothing announced by MCRB that day or the session before.

  2. 29 Oct 2026+8.9%

    Nothing announced by MCRB that day or the session before.

  3. 27 Oct 2026-9.1%
  4. 1 Oct 2026-12.5%

    Nothing announced by MCRB that day or the session before.

  5. 16 Sep 2026-8.5%

    Nothing announced by MCRB that day or the session before.

  6. 8 Jul 2026-12.3%
  7. 29 Jun 2026+10.0%

    Nothing announced by MCRB that day or the session before.

  8. 12 Jun 2026-9.8%

    Nothing announced by MCRB that day or the session before.

  9. 4 Jun 2026-4.5%

    Nothing announced by MCRB that day or the session before.

  10. 1 Jun 2026+4.4%

Share of unusual movement by asset

For each asset, the share of MCRB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
SER-155
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—91%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Gut microbiome (cultivated bacterial consortium)Microbiome therapeutic
Graft-versus-Host Disease
Bacterial Infections in Allogeneic Stem Cell Transplant

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 July 2026Topline resultSER-155SER-155 topline results in irEC investigator-sponsored study

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.6M$5.6M$21M$16M-$10M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.7M$9.1M$18M—-$22M operating cash flowreport ↗
2026-Q1$0.4M$13M$39M$20M-$16M operating cash flowreport ↗
2025-Q3$0.3M$13M$56M—$2.2M operating cash flowreport ↗
2025-Q2$0$13M$54M$20M-$13M operating cash flowreport ↗
2025-Q1$0$12M$68M—$27M operating cash flowreport ↗
2024-Q3$0$16M$77M—-$35M operating cash flowreport ↗
2024-Q2$0$18M$81M$33M-$40M operating cash flowreport ↗
2024-Q1$0$22M$120M$40M-$35M operating cash flowreport ↗
2023-Q3$0.3M$28M$178M+ $0 short-term inv.$48M-$59M operating cash flowreport ↗
2023-Q2$126M$47M$238M+ $0 short-term inv.—$66M operating cash flowreport ↗
2023-Q1-$0.5M$44M$103M+ $12M short-term inv.$71M-$77M operating cash flowreport ↗
2022-Q3$3.4M$43M$214M+ $28M short-term inv.$60M-$60M operating cash flowreport ↗
2022-Q2$1.2M$44M$135M+ $69M short-term inv.$65M-$50M operating cash flowreport ↗
2022-Q1$1.5M$40M$161M+ $95M short-term inv.$57M-$66M operating cash flowreport ↗
2021-Q3$127M$40M$227M+ $120M short-term inv.—$128M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.8M$49M$54M—$1.1M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$65M$39M—-$149M operating cash flowreport ↗
2023-FY$126M$146M$136M+ $0 short-term inv.$28M-$117M operating cash flowreport ↗
2022-FY$7.1M$173M$171M+ $18M short-term inv.$63M-$229M operating cash flowreport ↗
2021-FY$145M$142M$188M+ $111M short-term inv.$16M$6.7M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($11K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Henn Matthew R · See RemarksOpen-market sale101$1.38$139Form 4
2026-11-16Shaff Eric D. · directorOpen-market sale287$1.38$396Form 4
2026-11-16DesRosier Thomas · See RemarksOpen-market sale103$1.38$142Form 4
2026-11-16Brady Kelly · See RemarksOpen-market sale85$1.38$117Form 4
2026-11-15Henn Matthew R · See RemarksOption exercise238——Form 4
2026-11-15Shaff Eric D. · directorOption exercise724——Form 4
2026-11-15DesRosier Thomas · See RemarksOption exercise244——Form 4
2026-11-15Brady Kelly · See RemarksOption exercise181——Form 4